Genenta Science, a pioneer in the field of immuno-oncology listed on Nasdaq, announces that it has entered into a securities purchase agreement with institutional investors, US investment funds, for the purchase of 4,285,715 American Depositary Shares (ADS) at an offer price of $3.50 per ADS, for gross proceeds of approximately $15.0 million, gross of underwriting commissions and other estimated offering expenses. All securities in the offering were sold by Genenta and no warrants or other derivative securities were issued in connection with this offering, therefore no future dilution is expected.
Maxim Group is acting as lead placement agent for the offering, while Rodman & Renshaw is acting as co-placement agent for the offering.
Genenta intends to use the net proceeds from the offering for working capital and general corporate purposes. The offering is expected to close on 28 October 2025, subject to customary closing conditions.
The securities described above are being offered pursuant to a preliminary registration statement on Form F-3 (file number 333-271901) previously filed with the US Securities and Exchange Commission (SEC) and declared effective on 24 May 2023. A prospectus supplement relating to the securities to be issued in connection with the offering will be filed by the Company with the SEC.
The press release issued by Genenta announcing the transaction does not constitute an offer to sell or a solicitation of an offer to purchase any such securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. (pictured: Pierluigi Paracchi, CEO of Genenta).
ALL RIGHTS RESERVED ©